Atlas market file · Equity · United States
Inflection Point Acquisition Corp. VIPEX
- Last close
- 10.52
- Change
- +0.00%
- 96-bar range
- 10.37 – 10.59
- As of
- 6 Aug 2026
Inflection Point Acquisition Corp. V is a blank checks issuer listed as IPEX on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 76 weekly closes (+6.59% over the window).
Source rail: Yahoo Finance chart API (IPEX). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for IPEX. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
IPEX public profile
Blank checks issuer. Inflection Point Acquisition Corp. V is connected to current market context, cited company sources and its retained research file.
Inflection Point Acquisition Corp. V trades as IPEX on NASDAQ. Inflection Point Acquisition Corp. V (IPEX) has a latest verified close of 10.52, unchanged, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files IPEX under USA Stocks for browsing.
What changed for Inflection Point Acquisition Corp. V today
Inflection Point Acquisition Corp. V, a Cayman Islands-domiciled special purpose acquisition company, is asking its shareholders to vote on a merger with GOWell Technology Limited, a Cayman entity whose own SEC filings promise to reveal “important information” about itself and the proposed union. The deal’s proxy statement, filed on 20 July 2026, sets out the voting mechanics, webcast details, and a polite invitation to submit questions, all while the combined entity’s financial wherewithal remains conspicuously absent from the current filings. What GOWell actually does, how much it earns, and why it has chosen to merge with a SPAC whose operating loss already exceeded half a million dollars in the first quarter of 2026 are questions that the SEC documents do not yet answer. (source: SEC EDGAR DEF 14A, 2026-07-20, https://www.sec.gov/Archives/edgar/data/2028355/000121390026079622/ea0297364-02.htm)
SPACs exist to merge, liquidate, or return capital before the cash runway expires, yet Inflection Point’s latest 10-Q shows why urgency matters: as of 31 March 2026, the company reported operating losses of $545,794, net income of $240,456 (attributable to a reversal or one-off item not detailed in the filing), and a stockholders’ equity deficit of $6.6 million. Cash and equivalents sat at a mere $289,580 as of 30 September 2025, while operating activities used $214,882 of cash in the first three months of 2026. In other words, the company’s liquidity buffer is thinner than a PowerPoint slide on a rainy day. (source: IPEX 10-Q, 2026-05-15, https://www.sec.gov/Archives/edgar/data/2028355/000121390026057846/ea0290008-10q_inflection5.htm)
GOWell Technology’s proposed merger partner is a SPAC that, on paper, has $90.3 million of total assets and $6.8 million of liabilities as of 31 March 2026, yet its cash position has not been updated since September 2025. The 425 filing announcing the deal offers no pro forma financials, no revenue bridge, and no segment-level detail; instead, it simply notes that the definitive documents will be filed “when they become available.” Shareholders are thus asked to approve a merger whose underlying economics remain undisclosed, with the promise that the missing numbers will materialise later-an arrangement that would be called optimistic in venture capital and merely routine in SPAC-land. (source: IPEX 425, 2026-07-17, https://www.sec.gov/Archives/edgar/data/2028355/000121390026079198/ea0298139-8k425_inflection5.htm)
The extraordinary general meeting notice, posted alongside the proxy statement on the CST Proxy site, sets out the mechanics for voting and webcast participation, but it does not explain why the board is rushing to merge a cash-starved shell with an entity whose own financials are not yet public. The filing does, however, remind shareholders that they may attend, vote, or submit questions via a live webcast-a feature that is technically impressive but substantively irrelevant when the underlying deal’s numbers are still missing. (source: SEC EDGAR DEF 14A, 2026-07-20, https://www.sec.gov/Archives/edgar/data/2028355/000121390026079622/ea0297364-02.htm)
For now, the market is left with a shell company whose operating cash burn outpaced its revenue by a factor of infinity, a board that is asking for a merger vote without disclosing the target’s figures, and an SEC filing regime that treats “when they become available” as an acceptable disclosure standard. Until GOWell’s financials land, the best investors can do is read the filings like a choose-your-own-adventure story in which the punchline is still missing. (source: IPEX 10-Q, 2026-05-15, https://www.sec.gov/Archives/edgar/data/2028355/000121390026057846/ea0290008-10q_inflection5.htm)
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
IPEX technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on IPEX
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep IPEX research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
IPEX FAQ
What is Inflection Point Acquisition Corp. V (IPEX)?Inflection Point Acquisition Corp. V (IPEX) has a latest verified close of 10.52, unchanged, dated 6 Aug 2026. Use this page to check the price chart, company context,...
Inflection Point Acquisition Corp. V (IPEX) has a latest verified close of 10.52, unchanged, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for IPEX?Inflection Point Acquisition Corp. V (IPEX) has a latest verified close of 10.52, unchanged, dated 6 Aug 2026. It brings the latest available chart, company context,...
Inflection Point Acquisition Corp. V (IPEX) has a latest verified close of 10.52, unchanged, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files IPEX under USA Stocks for browsing.
How often is the IPEX page updated?The IPEX public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The IPEX public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for IPEX?The IPEX file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:IPEX. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The IPEX file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:IPEX. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on IPEX?Yes. The workstation can open IPEX, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open IPEX, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this IPEX page investment advice?No. The IPEX page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The IPEX page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →
IPEX
Equity · evidence first